🇺🇸 FDA
Patent

US 8507206

Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)

granted A61PA61P25/28

Quick answer

US patent 8507206 (Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)) held by Acumen Pharmaceuticals, Inc. expires Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Acumen Pharmaceuticals, Inc.
Grant date
Tue Aug 13 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 08 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
1
CPC classes
A61P, A61P25/28